knowledge -WSS

knowledge

author：hotspot 2025-10-01 18:44:50 - browse：492

Stock exchange — Drew Angerer/Getty Images

Viking Therapeutics said Tuesday that its closely watched oral obesity drug had succeeded in an early-stage trial and that it planned to advance the medicine into the next phase of development.

The top-line results released Tuesday were only from a Phase 1 study, which primarily focuses on a drug’s safety. But Viking said that in the study, its medicine led to a roughly 3.3% placebo-adjusted average weight loss after four weeks and that it showed no safety issues.

In preview notes, analysts had said that investors would want to see between 3% and 4% placebo-adjusted weight loss. Shares of San Diego-based Viking were up more than 20% in pre-market trading Tuesday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： The painfully weak evidence on taking collagen to treat arthritis

focus

WSS

Zapping the brain for stroke rehab: Pivotal clinical trial begins

Medicare inequities exacerbate Puerto Rico’s health disparities

CDC launches VaccineFinder tool to locate Covid

Biden praises World Series champion Astros for impact off the field during White House celebration

The Harvard botanist who searched for psychedelics in the Amazon

R1 RCM gets $5.8 billion buyout offer from private equity firm

hotspot

knowledge

hotspot

Trump demands the U.S. pay no more for drugs than other countries … again

The painfully weak evidence on taking collagen to treat arthritis

Continuity nursing helped my family in our darkest PICU moments

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

In Memoriam: Notable people who died in 2023

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

Duchenne breakthrough therapy leaves behind pioneering families

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Antivenom research: Lessons from HIV applied in search for universal antidote

focus

Hospitals use virtual reality to design more inclusive rooms for kids

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

Former Georgia lieutenant governor says he received grand jury subpoena

Hospitals use virtual reality to design more inclusive rooms for kids

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

Ohioans vote in high

focus

focus

hotspot

hotspot